Chelsea Therapeutics entered into two licensing agreements. Chelsea executed a letter of intent with Synergia Pharma to acquire all IP rights for Droxidopa. The second deal was with Active Biotech to co-develop and commercialize Active Biotech’s I-3D portfolio of orally active, dihydroorotate dehydrogenase-inhibitor compounds.